Japan drug price reforms risk hurting investment: Bristol-Myers CEO

  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 31 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 66%

United States News News

United States United States Latest News,United States United States Headlines

TOKYO: Japan's 'overly restrictive' drug pricing policies risk diverting foreign direct investment to China and other markets, the chief executive ...

TOKYO: Japan's"overly restrictive" drug pricing policies risk diverting foreign direct investment to China and other markets, the chief executive of Bristol-Myers Squibb said on Thursday.

"The world is very competitive, and countries such as China have made it a priority to develop a biopharmaceutical innovation-focused industry," Caforio said at an event organized by the Japan office of PhRMA, the main U.S. drugmaker lobby.Japan's government is seeking ways to squeeze savings from its national health care system as the population ages. The number of working-age people in Japan compared to those over the age of 65 is 1.

The rules announced last year evaluate drugs and their makers for innovation to determine how much the government will pay for treatments.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in US
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

WeWork Japan gets new CEO, days after We Company founder quitsWeWork Japan on Wednesday named a new head of local operations, just days after the co-founder of the We Company stepped down following a botched ... Thank you..❤
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »